GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » SenzaGen AB (OSTO:SENZA) » Definitions » Peter Lynch Fair Value

SenzaGen AB (OSTO:SENZA) Peter Lynch Fair Value : kr-8.83 (As of May. 28, 2025)


View and export this data going back to 2017. Start your Free Trial

What is SenzaGen AB Peter Lynch Fair Value?

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Here, as of today, SenzaGen AB's PEG is 1. SenzaGen AB's 5-Year TTM EBITDA Growth Rate is 25. SenzaGen AB's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2025 was kr-0.35. Therefore, the Peter Lynch Fair Value for today is kr-8.83.

As of today (2025-05-28), SenzaGen AB's share price is kr5.88. SenzaGen AB's Peter Lynch fair value is kr-8.83. Therefore, SenzaGen AB's Price to Peter Lynch Fair Value Ratio for today is N/A.


The historical rank and industry rank for SenzaGen AB's Peter Lynch Fair Value or its related term are showing as below:



OSTO:SENZA's Price-to-Peter-Lynch-Fair-Value is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 2.22
* Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


SenzaGen AB Peter Lynch Fair Value Historical Data

The historical data trend for SenzaGen AB's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SenzaGen AB Peter Lynch Fair Value Chart

SenzaGen AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Peter Lynch Fair Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

SenzaGen AB Quarterly Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Peter Lynch Fair Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of SenzaGen AB's Peter Lynch Fair Value

For the Diagnostics & Research subindustry, SenzaGen AB's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SenzaGen AB's Price-to-Peter-Lynch-Fair-Value Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, SenzaGen AB's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where SenzaGen AB's Price-to-Peter-Lynch-Fair-Value falls into.


;
;

SenzaGen AB Peter Lynch Fair Value Calculation

SenzaGen AB's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* 25 *-0.353
=-8.83

SenzaGen AB's EPS without NRI for the trailing twelve months (TTM) uses the latest annual data, which was kr-0.35.

* Note that for companies that do not have enough quarterly data to calculate the 5-Year TTM EBITDA Growth Rate, we use the annual data for the calculation.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


SenzaGen AB  (OSTO:SENZA) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 25 instead of 15 in this case.

SenzaGen AB's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=5.88/-8.83
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SenzaGen AB Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of SenzaGen AB's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.


SenzaGen AB Business Description

Traded in Other Exchanges
N/A
Address
Scheeletorget 1, Medicon Village, Building 401, Lund, SWE, 223 81
SenzaGen AB markets sells, and performs the in vitro Genomic Allergen Rapid Detection (GARD) sensitization test through its laboratory and licensed Contract Research Organizations (CROs) in Sweden. It offers animal-free testing of chemical compounds in cosmetics, pharmaceuticals, food products, and dyes. It operates in five market segments- Cosmetics, Chemicals, Medical devices, Pharmaceuticals, and Nutrition/food additives. The majority is from the Pharmaceuticals segment. Geographically it operates in North America, Europe, APAC, and RoW, the majority is from Europe.

SenzaGen AB Headlines

No Headlines